| (Values in U.S. Thousands) | Sep, 2016 | Sep, 2015 | Sep, 2014 | Sep, 2013 | Sep, 2012 |
| Sales | 2,080 | 3,110 | 9,630 | 3,930 | 7,290 |
| Sales Growth | -33.12% | -67.71% | +145.04% | -46.09% | +337.46% |
| Net Income | -3,560 | -2,630 | -80 | -3,210 | 1,700 |
| Net Income Growth | -35.36% | -3,187.54% | +97.51% | -288.82% | unch |
Aeolus Pharmaceuticals Inc (AOLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Aeolus is developing a new class of small molecule catalytic antioxidants that destroy oxygen-derived free radicals, believed to be an important contributor to the pathogenesis of many diseases. Aeolus' catalytic antioxidants have been shown to reduce damage to tissue in animal studies of ALS, stroke, cancer and chronic obstructive pulmonary disease.
Fiscal Year End Date: 09/30